Illinois SB1773 introduced to schedule xylazine as Class III controlled substance; bill text states effective Jan 1, 2026 (proposal)

SB1773 (104th General Assembly) proposes amendments to the Illinois Controlled Substances Act to schedule xylazine as a Class III controlled substance; the bill PDF synopsis states an effective date of 2026-01-01. An amendment document was also identified that adds xylazine exemption language (e.g., circumstances where xylazine would not be considered a controlled substance). Stakeholders should monitor because scheduling would create new controlled-substance compliance obligations for entities handling xylazine unless exempted.